or does claim 1 involve elements of process or method that take it outside the scope of that expression?
the patent is titled "injectable ready-to-use solutions containing an antitumor anthracycline glycoside".
the specific exception to the latter (an exception which proves the rule) is the provision for recombinant dna technology in s 70(2)(b).